AstraZeneca
🇬🇧United Kingdom
- Country
- 🇬🇧United Kingdom
- Ownership
- Public
- Employees
- 89.9K
- Market Cap
- $270.3B
- Website
- http://www.astrazeneca.co.uk
- Introduction
AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.
A National, Multicenter, Prospective, Observational Study to Assess Patient Characteristics, Treatment Algorithms and Disease Management of Hyperkalaemia Patients With Chronic Kidney Disease or Under Dialysis or With Heart Failure, Treated With Sodium Zirconium Cyclosilicate in Greece
Active, not recruiting
- Conditions
- Interventions
- First Posted Date
- 2023-12-29
- Last Posted Date
- 2024-11-01
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 125
- Registration Number
- NCT06185660
- Locations
- 🇬🇷
Research Site, Thessaloniki, Greece
Study of AZD9829 in CD123+ Hematological Malignancies
- First Posted Date
- 2023-12-22
- Last Posted Date
- 2024-12-16
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 65
- Registration Number
- NCT06179511
- Locations
- 🇬🇧
Research Site, Manchester, United Kingdom
Observational Study to Evaluate the Effect and Safety of Selumetinib in Pediatric Patients With NF1-PNs
Recruiting
- Conditions
- First Posted Date
- 2023-12-19
- Last Posted Date
- 2024-12-06
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 400
- Registration Number
- NCT06175637
- Locations
- 🇨🇳
Research Site, Nanjing, China
A Study to Assess the Efficacy, Safety and Tolerability of Different Doses of AZD0780 in Patients With Dyslipidemia
- First Posted Date
- 2023-12-15
- Last Posted Date
- 2024-10-08
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 428
- Registration Number
- NCT06173570
- Locations
- 🇪🇸
Research Site, Sevilla, Spain
A Study to Evaluate the Consistency of Oscillometry and Spirometry Test Results in Patients With Confirmed or Suspected Asthma or COPD
- First Posted Date
- 2023-12-15
- Last Posted Date
- 2024-08-22
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 800
- Registration Number
- NCT06172777
- Locations
- 🇨🇳
Research Site, Zigong, China
TrinetX Study of Hypereosinophilic Syndrome (HES) Without an Identifiable Non-haematological Secondary Cause
- First Posted Date
- 2023-12-15
- Last Posted Date
- 2024-05-29
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 250
- Registration Number
- NCT06172751
- Locations
- 🇺🇸
Research Site, Cambridge, Massachusetts, United States
REAl-world Outcomes in CHronic Lymphocytic Leukemia Patients Receiving Acalabrutinib in Romania
- First Posted Date
- 2023-12-14
- Last Posted Date
- 2024-12-16
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 250
- Registration Number
- NCT06170671
- Locations
- 🇷🇴
Research Site, Iasi, Romania
A Study to Investigate the Effect of Baxdrostat on Ambulatory Blood Pressure in Participants With Resistant Hypertension
- First Posted Date
- 2023-12-13
- Last Posted Date
- 2024-12-20
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 212
- Registration Number
- NCT06168409
- Locations
- 🇻🇳
Research Site, Hochiminh city, Vietnam
An ADME Study of [14C]AZD4604 and the Absolute Bioavailability of AZD4604
- First Posted Date
- 2023-12-05
- Last Posted Date
- 2024-05-29
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 8
- Registration Number
- NCT06157255
- Locations
- 🇬🇧
Research Site, Ruddington, United Kingdom
An Observational Study to Describe EVUSHELD™ (Tixagevimab/Cilgavimab) Pre-exposure Prophylaxis in Real-world Setting in Japan
- First Posted Date
- 2023-12-05
- Last Posted Date
- 2024-06-26
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 397
- Registration Number
- NCT06156982
- Locations
- 🇯🇵
Research Site, Osaka, Japan
© Copyright 2024. All Rights Reserved by MedPath